Kontrastmittelsonografie zur Charakterisierung von Lebertumoren: Praktische Aspekte

Zusammenfassung

In diesem Übersichtsartikel werden evidenzbasierte und praktische Aspekte zur Kontrastmittelsonografie von Leberraumforderungen dargestellt und kritisch bewertet. Neben den im Vergleich zur B-Bild-Sonografie verbesserten Möglichkeiten der Detektion und Charakterisierung werden Limitationen und Fehlermöglichkeiten dargestellt und ein Vergleich zu radiologischen Schnittbildverfahren gezogen. Behandelt werden auch Empfehlungen zur Wahl des Ultraschallgeräts und des Kontrastmittels sowie notwendige Qualifikationen des Untersuchers für eine sichere Befundinterpretation.

Abstract

This review article reports on evidence-based and clinical aspects of contrast-enhanced ultrasound of liver masses. The advanced possibilities of contrast-enhanced ultrasound to detect and characterise liver tumors are described as well as limitations and pitfalls of the method. The choice of the ultrasound device and contrast agents as well as the qualifications of the examiners according to guidelines are discussed.

Schlüsselwörter

Kontrastverstärkte Sonografie - Lebertumoren - fokal noduläre Hyperplasie - Hämangiom - Leberzelladenom - hepatozelluläres Karzinom

Key words

contrast-enhanced ultrasound - liver tumors - focal nodular hyperplasia - hemangioma - liver adenoma - hepatocellular carcinoma

• Literatur

• 1 Dietrich CF, Kratzer W, Strobel D et al. Assessment of metastatic liver disease in patients with primary extrahepatic tumors by contrast-enhanced sonography versus CT and MRI. World J Gastroenterol 2006; 12: 1699-1705
• 2 Dietrich CF, Ignee A, Trojan J et al. Improved characterisation of histologically proven liver tumours by contrast enhanced ultrasonography during the portal venous and specific late phase of SHU 508A. Gut 2004; 53: 401-405
• 3 Strobel D, Seitz K, Blank W et al. Contrast-enhanced ultrasound for the characterization of focal liver lesions--diagnostic accuracy in clinical practice (DEGUM multicenter trial). Ultraschall in Med 2008; 29: 499-505
• 4 Claudon M, Cosgrove D, Albrecht T et al. Guidelines and good clinical practice recommendations for contrast enhanced ultrasound (CEUS) – update 2008. Ultraschall in Med 2008; 29: 28-44
• 5 Piscaglia F, Nolsoe C, Dietrich CF et al. The EFSUMB Guidelines and Recommendations on the Clinical Practice of Contrast Enhanced Ultrasound (CEUS): update 2011 on non-hepatic applications. Ultraschall in Med 2012; 33: 33-59
• 6 Claudon M, Dietrich CF, Choi BI et al. Guidelines and good clinical practice recommendations for contrast enhanced ultrasound (CEUS) in the liver--update 2012: a WFUMB-EFSUMB initiative in cooperation with representatives of AFSUMB, AIUM, ASUM, FLAUS and ICUS. Ultraschall in Med 2013; 34: 11-29
• 7 Claudon M, Dietrich CF, Choi BI et al. Guidelines and good clinical practice recommendations for Contrast Enhanced Ultrasound (CEUS) in the liver – update 2012: A WFUMB-EFSUMB initiative in cooperation with representatives of AFSUMB, AIUM, ASUM, FLAUS and ICUS. Ultrasound Med Biol 2013; 39: 187-210
• 8 Dietrich CF, Averkiou MA, Correas JM et al. An EFSUMB introduction into Dynamic Contrast-Enhanced Ultrasound (DCE-US) for quantification of tumour perfusion. Ultraschall in Med 2012; 33: 344-351
• 9 Dietrich CF, Cui XW, Boozari B et al. Contrast-enhanced ultrasound (CEUS) in the diagnostic algorithm of hepatocellular and cholangiocellular carcinoma, comments on the AASLD guidelines. Ultraschall in Med 2012; 33: S57-S66
• 10 Barreiros AP, Piscaglia F, Dietrich CF. Contrast enhanced ultrasound for the diagnosis of hepatocellular carcinoma (HCC): comments on AASLD guidelines. J Hepatol 2012; 57: 930-932
• 11 Dietrich CF, Cui XW, Schreiber-Dietrich DG et al. EFSUMB guidelines 2011: comments and illustrations. Ultraschall in Med 2012; 33: S11-S21
• 12 Dietrich CF. Liver tumor characterization--comments and illustrations regarding guidelines. Ultraschall in Med 2012; 33: S22-S30
• 13 Bernatik T, Seitz K, Blank W et al. Unclear focal liver lesions in contrast-enhanced ultrasonography--lessons to be learned from the DEGUM multicenter study for the characterization of liver tumors. Ultraschall in Med 2010; 31: 577-581
• 14 Seitz K, Greis C, Schuler A et al. Frequency of tumor entities among liver tumors of unclear etiology initially detected by sonography in the noncirrhotic or cirrhotic livers of 1349 patients. Results of the DEGUM multicenter study. Ultraschall in Med 2011; 32: 598-603
• 15 Seitz K, Strobel D, Bernatik T et al. Contrast-Enhanced Ultrasound (CEUS) for the characterization of focal liver lesions – prospective comparison in clinical practice: CEUS vs. CT (DEGUM multicenter trial). Parts of this manuscript were presented at the Ultrasound Dreilandertreffen 2008, Davos. Ultraschall in Med 2009; 30: 383-389
• 16 Strobel D, Seitz K, Blank W et al. Tumor-specific vascularization pattern of liver metastasis, hepatocellular carcinoma, hemangioma and focal nodular hyperplasia in the differential diagnosis of 1349 liver lesions in contrast-enhanced ultrasound (CEUS). Ultraschall in Med 2009; 30: 376-382
• 17 Strobel D, Bernatik T, Blank W et al. Diagnostic accuracy of CEUS in the differential diagnosis of small (</= 20 mm) and subcentimetric (</= 10 mm) focal liver lesions in comparison with histology. Results of the DEGUM multicenter trial. Ultraschall in Med 2011; 32: 593-597
• 18 Westwood M, Joore M, Grutters J et al. Contrast-enhanced ultrasound using SonoVue(R) (sulphur hexafluoride microbubbles) compared with contrast-enhanced computed tomography and contrast-enhanced magnetic resonance imaging for the characterisation of focal liver lesions and detection of liver metastases: a systematic review and cost-effectiveness analysis. Health Technol Assess 2013; 17 (16) 1-243
• 19 Lorusso A, Quaia E, Poillucci G et al. Activity-based cost analysis of contrast-enhanced ultrasonography (CEUS) related to the diagnostic impact in focal liver lesion characterisation. Insights Imaging 2015; [epub ahead of print]
• 20 Dietrich CF, Riemer-Hommel P. Challenges for the German Health Care System. Z Gastroenterol 2012; 50: 557-572
• 21 Dietrich CF, Mäurer M, Riemer-Hommel P. Challenges for the German Health Care System. Pharmaceuticals. Endo heute 2014; 27: 45-53
• 22 Dietrich CF. Editorial on the contribution "Challenges for the German Health Care System". Z Gastroenterol 2012; 50: 555-556
• 23 Schreiber-Dietrich D, Dietrich CF. Contrast enhanced ultrasound (CEUS) and off-label use (in children). Ultraschall in Med 2012; 33: 295-296
• 24 Schreiber-Dietrich DG, Cui XW, Piscaglia F et al. Contrast enhanced ultrasound in pediatric patients: a real challenge. Z Gastroenterol 2014; 52 (10) 1178-1184
• 25 Albrecht T, Blomley M, Bolondi L et al. Guidelines for the use of contrast agents in ultrasound. Ultraschall in Med 2004; 25: 249-256
• 26 Dietrich CF, Schreiber-Dietrich D, Schuessler G et al. Contrast enhanced ultrasound of the liver--state of the art. Dtsch Med Wochenschr 2007; 132 (22) 1225-1231
• 27 Dietrich CF. Characterisation of focal liver lesions with contrast enhanced ultrasonography. Eur J Radiol 2004; 51 Suppl: S9-S17
• 28 von Herbay A, Haeussinger D, Gregor M et al. Characterization and detection of hepatocellular carcinoma (HCC): comparison of the ultrasound contrast agents SonoVue (BR 1) and Levovist (SH U 508A). Ultraschall in Med 2007; 28: 168-175
• 29 Sugimoto K, Moriyasu F, Saito K et al. Comparison of Kupffer-phase Sonazoid-enhanced sonography and hepatobiliary-phase gadoxetic acid-enhanced magnetic resonance imaging of hepatocellular carcinoma and correlation with histologic grading. J Ultrasound Med 2012; 31: 529-538
• 30 Dietrich CF, Rudd L. The EFSUMB website, a guide for better understanding. Med Ultrason 2013; 15: 215-223
• 31 Bernatik T, Becker D, Neureiter D et al. Detection of liver metastases--comparison of contrast-enhanced ultrasound using first versus second generation contrast agents. Ultraschall in Med 2003; 24: 175-179
• 32 Bernatik T, Strobel D, Hahn EG et al. Detection of liver metastases: comparison of contrast-enhanced wide-band harmonic imaging with conventional ultrasonography. J Ultrasound Med 2001; 20: 509-515
• 33 Oldenburg A, Hohmann J, Foert E et al. Detection of hepatic metastases with low MI real time contrast enhanced sonography and SonoVue. Ultraschall in Med 2005; 26: 277-284
• 34 Albrecht T, Blomley MJ, Burns PN et al. Improved detection of hepatic metastases with pulse-inversion US during the liver-specific phase of SHU 508A: multicenter study. Radiology 2003; 227: 361-370
• 35 von Herbay A, Vogt C, Haussinger D. Late-phase pulse-inversion sonography using the contrast agent levovist: differentiation between benign and malignant focal lesions of the liver. Am J Roentgenol Am J Roentgenol 2002; 179: 1273-1279
• 36 Piscaglia F, Cucchetti A, Dietrich CF et al. Towards new tools for refined management of patients with advanced hepatocellular carcinoma under systemic therapy: some enthusiasm with a word of caution. J Hepatol 2013; 59: 924-925
• 37 Dietrich CF, Schuessler G, Trojan J et al. Differentiation of focal nodular hyperplasia and hepatocellular adenoma by contrast-enhanced ultrasound. Br J Radiol 2005; 78 (932) 704-707
• 38 Cui XW, Ignee A, Jedrzejczyk M et al. Dynamic Vascular Pattern (DVP), a quantification tool for contrast enhanced ultrasound. Z Gastroenterol 2013; 51: 427-431
• 39 Wilson SR, Burns PN. An algorithm for the diagnosis of focal liver masses using microbubble contrast-enhanced pulse-inversion sonography. Am J Roentgenol Am J Roentgenol 2006; 186: 1401-1412
• 40 Piscaglia F, Venturi A, Mancini M et al. Diagnostic features of real-time contrast-enhanced ultrasound in focal nodular hyperplasia of the liver. Ultraschall in Med 2010; 31: 276-282
• 41 Bosman FT, Carneiro F, Hruban RH et al. WHO Classification of Tumours of the Digestive System. 4ed. World Health Organisation; 2010
• 42 Shanbhogue A, Shah SN, Zaheer A et al. Hepatocellular adenomas: current update on genetics, taxonomy, and management. J Comput Assist Tomogr 2011; 35: 159-166
• 43 Bioulac-Sage P, Rebouissou S, Thomas C et al. Hepatocellular adenoma subtype classification using molecular markers and immunohistochemistry. Hepatology 2007; 46: 740-748
• 44 Balabaud C, Al Rabih WR, Chen PJ et al. Focal Nodular Hyperplasia and Hepatocellular Adenoma around the World Viewed through the Scope of the Immunopathological Classification. Int J Hepatol 2013; 2013: 268625
• 45 Laumonier H, Cailliez H, Balabaud C et al. Role of contrast-enhanced sonography in differentiation of subtypes of hepatocellular adenoma: correlation with MRI findings. Am J Roentgenol Am J Roentgenol 2012; 199: 341-348
• 46 Manichon AF, Bancel B, Durieux-Millon M et al. Hepatocellular adenoma: evaluation with contrast-enhanced ultrasound and MRI and correlation with pathologic and phenotypic classification in 26 lesions. HPB Surg 2012; 2012: 418745
• 47 Dietrich CF, Schuessler G, Trojan J et al. Differentiation of focal nodular hyperplasia and hepatocellular adenoma by contrast-enhanced ultrasound. Br J Radiol 2005; 78 (932) 704-707
• 48 Hirche TO, Ignee A, Hirche H et al. Evaluation of hepatic steatosis by ultrasound in patients with chronic hepatitis C virus infection. Liver Int 2007; 27: 748-757
• 49 Strobel D, Kleinecke C, Hansler J et al. Contrast-enhanced sonography for the characterisation of hepatocellular carcinomas--correlation with histological differentiation. Ultraschall in Med 2005; 26: 270-276
• 50 Bolondi L, Gaiani S, Celli N et al. Characterization of small nodules in cirrhosis by assessment of vascularity: the problem of hypovascular hepatocellular carcinoma. Hepatology 2005; 42: 27-34
• 51 Ignee A, Weiper D, Schuessler G et al. Sonographic characterisation of hepatocellular carcinoma at time of diagnosis. Z Gastroenterol 2005; 43: 289-294
• 52 Gaiani S, Celli N, Piscaglia F et al. Usefulness of contrast-enhanced perfusional sonography in the assessment of hepatocellular carcinoma hypervascular at spiral computed tomography. J Hepatol 2004; 41: 421-426
• 53 Bolondi L. Screening for hepatocellular carcinoma in cirrhosis. J Hepatol 2003; 39: 1076-1084
• 54 Mork H, Ignee A, Schuessler G et al. Analysis of neuroendocrine tumour metastases in the liver using contrast enhanced ultrasonography. Scand J Gastroenterol 2007; 42: 652-662
• 55 Dietrich CF, Maddalena ME, Cui XW et al. Liver tumor characterization--review of the literature. Ultraschall in Med 2012; 33 Suppl 1: S3-10
• 56 Wildner D, Pfeifer L, Goertz RS et al. Dynamic contrast-enhanced ultrasound (DCE-US) for the characterization of hepatocellular carcinoma and cholangiocellular carcinoma. Ultraschall in Med 2014; 35: 522-527
• 57 Wildner D, Bernatik T, Greis C et al. CEUS in Hepatocellular Carcinoma and Intrahepatic Cholangiocellular Carcinoma in 320 Patients – Early or Late Washout Matters: A Subanalysis of the DEGUM Multicenter Trial. Ultraschall in Med 2015; 36: 132-139
• 58 Dietrich CF, Mertens JC, Braden B et al. Contrast-enhanced ultrasound of histologically proven liver hemangiomas. Hepatology 2007; 45: 1139-1145
• 59 Morita Y, Shirado H, Shinohara M et al. Arterial-portal shunt in cavernous hemangioma of the liver. Rinsho Hoshasen 1983; 28 (12) 1507-1510
• 60 Morita M, Sakakiyama Y, Shiono H et al. An autopsy case of a cavernous hemangioma with solitary fibromatous fibrosis within the cavernous space in the liver of an adult. Sapporo Igaku Zasshi 1970; 38: 1-7
• 61 Girard C, Graham JH, Johnson WC. Arteriovenous hemangioma (arteriovenous shunt). A clinicopathological and histochemical study. J Cutan Pathol 1974; 1: 73-87
• 62 Mostbeck A, Grunert V, Valencak E. Angioscintigraphy and shunt volume determination in a.-v. hemangiomas. Wien Med Wochenschr 1970; 120 (47) 872-875
• 63 Schuessler G, Ignee A, Hirche T et al. Improved detection and characterisation of liver tumors with echo-enhanced ultrasound. Z Gastroenterol 2003; 41: 1167-1176
• 64 Rickes S, Wermke T, Ocran K et al. Contrast behaviour of a angiomyolipoma of the liver at echo-enhanced power-Doppler sonography. Ultraschall in Med 2002; 23: 338-340
• 65 Rickes S, Ocran K, Schulze S et al. Evaluation of Doppler sonographic criteria for the differentiation of hepatocellular carcinomas and regenerative nodules in patients with liver cirrhosis. Ultraschall in Med 2002; 23: 83-90
• 66 Rickes S, Ocran KW, Gerstenhauer G et al. Evaluation of diagnostic criteria for liver metastases of adenocarcinomas and neuroendocrine tumours at conventional ultrasound, unenhanced power Doppler sonography and echo-enhanced ultrasound. Dig Dis 2004; 22: 81-86
• 67 Bauditz J, Rudolph B, Wermke W. Osteoclast-like giant cell tumors of the pancreas and liver. World J Gastroenterol 2006; 12: 7878-7883
• 68 Hansler J, Witte A, Strobel D et al. Radio-frequency-ablation (RFA) with wet electrodes in the treatment of primary and secondary liver tumours. Ultraschall in Med 2003; 24: 27-33
• 69 Hansler J, Neureiter D, Wasserburger M et al. Percutaneous US-guided radiofrequency ablation with perfused needle applicators: improved survival with the VX2 tumor model in rabbits. Radiology 2004; 230: 169-174
• 70 Frieser M, Schaber S, Peters A et al. Radiofrequency ablation using perfused needle electrodes – study of intermittent and continuous triple needle application ex vivo. Eur Surg Res 2005; 37: 312-316
• 71 Hansler J, Wissniowski TT, Schuppan D et al. Activation and dramatically increased cytolytic activity of tumor specific T lymphocytes after radio-frequency ablation in patients with hepatocellular carcinoma and colorectal liver metastases. World J Gastroenterol 2006; 12: 3716-3721
• 72 Lencioni R, Cioni D, Crocetti L et al. Early-stage hepatocellular carcinoma in patients with cirrhosis: long-term results of percutaneous image-guided radiofrequency ablation. Radiology 2005; 234: 961-967
• 73 Plentz RR, Lankisch TO, Basturk M et al. Prospective analysis of German patients with hepatocellular carcinoma undergoing transcatheter arterial chemoembolization with or without prophylactic antibiotic therapy. J Gastroenterol Hepatol 2005; 20: 1134-1136
• 74 Dettmer A, Kirchhoff TD, Gebel M et al. Combination of repeated single-session percutaneous ethanol injection and transarterial chemoembolisation compared to repeated single-session percutaneous ethanol injection in patients with non-resectable hepatocellular carcinoma. World J Gastroenterol 2006; 12: 3707-3715
• 75 Dietrich CF, Nuernberg D. Interventioneller Ultraschall. Lehrbuch und Atlas für die Interventionelle Sonografie. Stuttgart, New York: Thieme; 2011
• 76 Goldberg SN, Solbiati L. Tumor dissemination after radiofrequency ablation of hepatocellular carcinoma. Hepatology 2001; 34: 609-1
• 77 Solbiati L, Ierace T, Tonolini M et al. Radiofrequency thermal ablation of hepatic metastases. Eur J Ultrasound 2001; 13: 149-158
• 78 Solbiati L, Ierace T, Tonolini M et al. Guidance and monitoring of radiofrequency liver tumor ablation with contrast-enhanced ultrasound. Eur J Radiol 2004; 51: S19-S23
• 79 Livraghi T, Solbiati L, Meloni F et al. Percutaneous radiofrequency ablation of liver metastases in potential candidates for resection: the "test-of-time approach". Cancer 2003; 97: 3027-3035
• 80 Frieser M, Kiesel J, Lindner A et al. Efficacy of contrast-enhanced US versus CT or MRI for the therapeutic control of percutaneous radiofrequency ablation in the case of hepatic malignancies. Ultraschall in Med 2011; 32: 148-153
• 81 Dong Y, Wang WP, Gan YH et al. Radiofrequency ablation guided by contrast-enhanced ultrasound for hepatic malignancies: preliminary results. Clin Radiol 2014; 69: 1129-1135
• 82 Mauri G, Porazzi E, Cova L et al. Intraprocedural contrast-enhanced ultrasound (CEUS) in liver percutaneous radiofrequency ablation: clinical impact and health technology assessment. Insights Imaging 2014; 5: 209-216
• 83 Minami Y, Nishida N, Kudo M. Therapeutic response assessment of RFA for HCC: contrast-enhanced US, CT and MRI. World J Gastroenterol 2014; 20: 4160-4166
• 84 Inoue T, Kudo M, Hatanaka K et al. Usefulness of contrast-enhanced ultrasonography to evaluate the post-treatment responses of radiofrequency ablation for hepatocellular carcinoma: comparison with dynamic CT. Oncology 2013; 84: 51-57
• 85 Shiozawa K, Watanabe M, Takayama R et al. Evaluation of local recurrence after treatment for hepatocellular carcinoma by contrast-enhanced ultrasonography using Sonazoid: comparison with dynamic computed tomography. J Clin Ultrasound 2010; 38: 182-189
• 86 Du J, Li HL, Zhai B et al. Radiofrequency Ablation for Hepatocellular Carcinoma: Utility of Conventional Ultrasound and Contrast-enhanced Ultrasound in Guiding and Assessing Early Therapeutic Response and Short-term Follow-up Results. Ultrasound Med Biol 2015; [epub ahead of print]
• 87 Catalano O, Izzo F, Vallone P et al. Integrating contrast-enhanced sonography in the follow-up algorithm of hepatocellular carcinoma treated with radiofrequency ablation: single cancer center experience. Acta Radiol 2015; 56: 133-142
• 88 Dietrich CF, Ignee A, Greis C et al. Artifacts and pitfalls in contrast-enhanced ultrasound of the liver. Ultraschall in Med 2014; 35: 108-125
• 89 Dietrich CF, Ignee A, Hocke M et al. Pitfalls and artefacts using contrast enhanced ultrasound. Z Gastroenterol 2011; 49: 350-356
• 90 Cui XW, Ignee A, Hocke M et al. Prolonged Heterogeneous Liver Enhancement on Contrast-Enhanced Ultrasound. Ultraschall in Med 2014; 35: 246-252
• 91 Goertz RS, Janka R, Nagel A et al. Eosinophilic infiltration of the liver and pancreas mimicking metastatic disease. Z Gastroenterol 2010; 48: 1138-1140
• 92 Gossmann J, Scheuermann EH, Frilling A et al. Multiple adenomas and hepatocellular carcinoma in a renal transplant patient with glycogen storage disease type 1a (von Gierke disease). Transplantation 2001; 72: 343-344
• 93 Schuessler G, Fellbaum C, Fauth F et al. The Inflammatory Pseudotumour – an Unusual Liver Tumour. Ultraschall in Med 2006; 27: 273-279
• 94 Trojan J, Hammerstingl R, Engels K et al. Contrast-enhanced ultrasound in the diagnosis of malignant mesenchymal liver tumors. J Clin Ultrasound 2010; 38: 227-231
• 95 Chiorean L, Cantisani V, Jenssen C et al. Focal masses in a non-cirrhotic liver: The additional benefit of CEUS over baseline imaging. Eur J Radiol 2015; [epub ahead of print]
• 96 Chiorean L, Caraiani C, Radzina M et al. Vascular phases in imaging and their role in focal liver lesions assessment. J Clin Hemorheol Microcirculation 2015; in press.
• 97 Brenner DJ, Doll R, Goodhead DT et al. Cancer risks attributable to low doses of ionizing radiation: assessing what we really know. Proc Natl Acad Sci U S A 2003; 100: 13761-13766
• 98 Hall EJ, Brenner DJ. Cancer risks from diagnostic radiology. Br J Radiol 2008; 81: 362-378
• 99 Brenner DJ, Hall EJ. Computed tomography--an increasing source of radiation exposure. N Engl J Med 2007; 357: 2277-2284
• 100 Hricak H, Brenner DJ, Adelstein SJ et al. Managing radiation use in medical imaging: a multifaceted challenge. Radiology 2011; 258: 889-905
• 101 Stacul F, van der Molen AJ, Reimer P et al. Contrast induced nephropathy: updated ESUR Contrast Media Safety Committee guidelines. Eur Radiol 2011; 21: 2527-2541
• 102 Morcos SK, Thomsen HS, Exley CM. Contrast media: interactions with other drugs and clinical tests. Eur Radiol 2005; 15: 1463-1468
• 103 van der Molen AJ, Thomsen HS, Morcos SK. Effect of iodinated contrast media on thyroid function in adults. Eur Radiol 2004; 14: 902-907
• 104 Thomsen HS, Morcos SK. ESUR guidelines on contrast media. Abdom Imaging 2006; 31: 131-140
• 105 Bellin MF, Stacul F, Webb JA et al. Late adverse reactions to intravascular iodine based contrast media: an update. Eur Radiol 2011; 21: 2305-2310
• 106 Morcos SK, Bellin MF, Thomsen HS et al. Reducing the risk of iodine-based and MRI contrast media administration: recommendation for a questionnaire at the time of booking. Eur J Radiol 2008; 66: 225-229
• 107 Bellin MF, Webb JA, van der Molen AJ et al. Safety of MR liver specific contrast media. Eur Radiol 2005; 15: 1607-1614
• 108 Jakobsen JA, Oyen R, Thomsen HS et al. Safety of ultrasound contrast agents. Eur Radiol 2005; 15: 941-945
• 109 Thomsen HS, Morcos SK, Almen T et al. Nephrogenic systemic fibrosis and gadolinium-based contrast media: updated ESUR Contrast Medium Safety Committee guidelines. Eur Radiol 2013; 23: 307-318
• 110 Piscaglia F, Bolondi L. The safety of Sonovue in abdominal applications: retrospective analysis of 23188 investigations. Ultrasound Med Biol 2006; 32: 1369-1375
• 111 Szebeni J, Muggia F, Gabizon A et al. Activation of complement by therapeutic liposomes and other lipid excipient-based therapeutic products: prediction and prevention. Adv Drug Deliv Rev 2011; 63: 1020-1030
• 112 Szebeni J, Baranyi L, Savay S et al. Role of complement activation in hypersensitivity reactions to doxil and hynic PEG liposomes: experimental and clinical studies. J Liposome Res 2002; 12: 165-172
• 113 Kitzman DW, Goldman ME, Gillam LD et al. Efficacy and safety of the novel ultrasound contrast agent perflutren (definity) in patients with suboptimal baseline left ventricular echocardiographic images. Am J Cardiol 2000; 86: 669-674
• 114 Dietrich CF. 3D real time contrast enhanced ultrasonography, a new technique. Rofo 2002; 174: 160-163
• 115 Hocke M, Schulze E, Gottschalk P et al. Contrast-enhanced endoscopic ultrasound in discrimination between focal pancreatitis and pancreatic cancer. World J Gastroenterol 2006; 12: 246-250
• 116 Min JH, Lim HK, Lim S et al. Radiofrequency ablation of very-early-stage hepatocellular carcinoma inconspicuous on fusion imaging with B-mode US: value of fusion imaging with contrast-enhanced US. Clin Mol Hepatol 2014; 20: 61-70
• 117 Minami T, Minami Y, Chishina H et al. Combination guidance of contrast-enhanced US and fusion imaging in radiofrequency ablation for hepatocellular carcinoma with poor conspicuity on contrast-enhanced US/fusion imaging. Oncology 2014; 87: 55-62
• 118 Lee MW, Rhim H, Cha DI et al. Planning US for percutaneous radiofrequency ablation of small hepatocellular carcinomas (1–3 cm): value of fusion imaging with conventional US and CT/MR images. J Vasc Interv Radiol 2013; 24: 958-965
• 119 Frohlich E, Muller R, Cui XW et al. Dynamic contrast-enhanced ultrasound for quantification of tissue perfusion. J Ultrasound Med 2015; 34: 179-196
• 120 Ignee A, Jedrejczyk M, Schuessler G et al. Quantitative contrast enhanced ultrasound of the liver for time intensity curves-Reliability and potential sources of errors. Eur J Radiol 2010; 73: 153-158
• 121 Zocco MA, Garcovich M, Lupascu A et al. Early prediction of response to sorafenib in patients with advanced hepatocellular carcinoma: the role of dynamic contrast enhanced ultrasound. J Hepatol 2013; 59: 1014-1021
• 122 Knieling F, Waldner MJ, Goertz RS et al. Early response to anti-tumoral treatment in hepatocellular carcinoma--can quantitative contrast-enhanced ultrasound predict outcome?. Ultraschall in Med 2013; 34: 38-46